Qualigen Therapeutics Enters Material Definitive Agreement
Ticker: AIXC · Form: 8-K · Filed: Sep 9, 2024 · CIK: 1460702
Sentiment: neutral
Topics: material-definitive-agreement, corporate-update
TL;DR
Qualigen Therapeutics signed a big deal on 9/6/24.
AI Summary
Qualigen Therapeutics, Inc. announced on September 6, 2024, that it entered into a material definitive agreement. The company, formerly known as Ritter Pharmaceuticals Inc., is incorporated in Delaware and headquartered in Carlsbad, California.
Why It Matters
This filing indicates a significant new contract or partnership for Qualigen Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements can carry inherent risks related to the terms, counterparty, and execution of the agreement.
Key Numbers
- 001-37428 — SEC File Number (Identifies the company's filing history with the SEC.)
- 26-3474527 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- Ritter Pharmaceuticals Inc. (company) — Former company name
- September 6, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Carlsbad, California (location) — Principal executive offices location
FAQ
What type of material definitive agreement did Qualigen Therapeutics enter into?
The filing states that Qualigen Therapeutics, Inc. entered into a material definitive agreement on September 6, 2024, but does not specify the nature of the agreement in the provided text.
When was Qualigen Therapeutics, Inc. formerly known as Ritter Pharmaceuticals Inc.?
The company's name change from Ritter Pharmaceuticals Inc. to Qualigen Therapeutics, Inc. occurred on April 2, 2009.
Where are Qualigen Therapeutics, Inc.'s principal executive offices located?
The principal executive offices of Qualigen Therapeutics, Inc. are located at 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.
What is the fiscal year end for Qualigen Therapeutics, Inc.?
The fiscal year end for Qualigen Therapeutics, Inc. is December 31.
What is the SIC code for Qualigen Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Qualigen Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 908 words · 4 min read · ~3 pages · Grade level 11.3 · Accepted 2024-09-09 17:15:12
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share QLGN The Nasdaq Capital M
- $0.13 — e "Shares") at public offering price of $0.13 per Share and pre-funded warrants to pu
- $0.129 — e up to 11,972,754 Shares at a price of $0.129 per share with an exercise price of $0.
- $3.47 m — ny received aggregate gross proceeds of $3.47 million, before payment of placement agen
- $0.156 — issuance, and has an exercise price of $0.156 per share of common stock. The Company
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex4-1.htm (EX-4.1) — 112KB
- ex4-2.htm (EX-4.2) — 143KB
- ex10-1.htm (EX-10.1) — 58KB
- ex99-1.htm (EX-99.1) — 12KB
- 0001493152-24-035508.txt ( ) — 611KB
- qlgn-20240906.xsd (EX-101.SCH) — 3KB
- qlgn-20240906_lab.xml (EX-101.LAB) — 33KB
- qlgn-20240906_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: September 9, 2024 By: /s/ Michael S. Poirier Michael S. Poirier, Chief Executive Officer